Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2000 Feb;82(4):865–870. doi: 10.1054/bjoc.1999.1013

Role and new perspectives of transforming growth factor-α (TGF- α) in adenocarcinoma of the gastro-oesophageal junction

A D'Errico 1, C Barozzi 1, M Fiorentino 1, R Carella 1, M Di Simone 2, L Ferruzzi 2, S Mattioli 2, W F Grigioni 1
PMCID: PMC2374390  PMID: 10732760

Abstract

The incidence of gastro-oesophageal junction (GEJ) adenocarcinoma is increasing in Western countries and prognosis is poor since metastasis is most often present at diagnosis. We examined samples from 87 resected type II GEJ adenocarcinomas, 30 of these with endoscopic diagnostic biopsy material, to evaluate transforming growth factor alpha (TGF-α) expression and p53 overexpression by immunohistochemistry and in situ hybridization (for TGF-α), in relation to biological and clinical behaviour. TGF-α messenger RNA (mRNA) and protein were detectable in neoplastic cells in 56% and 64% cases respectively. TGF-α mRNA was detected in intra- and peritumoral lymphocytes and those of metastatic lymph nodes. TGF-α protein expression was significantly associated with tumour progression (P = 0.025) and lymph node metastasis (P< 0.05). The strong TGF-α expression found in neoplastic cells inside blood and lymphatic vessels and in metastatic localizations suggests that TGF-α-positive GEJ adenocarcinomas could have a more aggressive biological phenotype. The expression of TGF-α mRNA and protein in both inflammatory and neoplastic cells indicates that TGF-α is directly synthesized by both cell compartments. Finally, since TGF-α expression was associated with lymph node metastasis, its detection in preoperative perendoscopic biopsies might identify patients with more aggressive tumours who may need additional therapy, including neo-adjuvant treatment. © 2000 Cancer Research Campaign

Keywords: TGF-α, adenocarcinoma, gastro-oesophageal junction

Full Text

The Full Text of this article is available as a PDF (281.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bajaj-Elliott M., Poulsom R., Pender S. L., Wathen N. C., MacDonald T. T. Interactions between stromal cell--derived keratinocyte growth factor and epithelial transforming growth factor in immune-mediated crypt cell hyperplasia. J Clin Invest. 1998 Oct 15;102(8):1473–1480. doi: 10.1172/JCI2792. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Blot W. J., Devesa S. S., Kneller R. W., Fraumeni J. F., Jr Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA. 1991 Mar 13;265(10):1287–1289. [PubMed] [Google Scholar]
  3. Bosch A., Frias Z., Caldwell W. L. Adenocarcinoma of the esophagus. Cancer. 1979 Apr;43(4):1557–1561. doi: 10.1002/1097-0142(197904)43:4<1557::aid-cncr2820430450>3.0.co;2-l. [DOI] [PubMed] [Google Scholar]
  4. Cai Y. C., Barnard G., Hiestand L., Woda B., Colby J., Banner B. Florid angiogenesis in mucosa surrounding an ileal carcinoid tumor expressing transforming growth factor-alpha. Am J Surg Pathol. 1997 Nov;21(11):1373–1377. doi: 10.1097/00000478-199711000-00013. [DOI] [PubMed] [Google Scholar]
  5. Casson A. G., Kerkvliet N., O'Malley F. Prognostic value of p53 protein in esophageal adenocarcinoma. J Surg Oncol. 1995 Sep;60(1):5–11. doi: 10.1002/jso.2930600103. [DOI] [PubMed] [Google Scholar]
  6. Casson A. G., Mukhopadhyay T., Cleary K. R., Ro J. Y., Levin B., Roth J. A. p53 gene mutations in Barrett's epithelium and esophageal cancer. Cancer Res. 1991 Aug 15;51(16):4495–4499. [PubMed] [Google Scholar]
  7. Coggi G., Bosari S., Roncalli M., Graziani D., Bossi P., Viale G., Buffa R., Ferrero S., Piazza M., Blandamura S. p53 protein accumulation and p53 gene mutation in esophageal carcinoma. A molecular and immunohistochemical study with clinicopathologic correlations. Cancer. 1997 Feb 1;79(3):425–432. doi: 10.1002/(sici)1097-0142(19970201)79:3<425::aid-cncr1>3.0.co;2-h. [DOI] [PubMed] [Google Scholar]
  8. De Jong K. P., Stellema R., Karrenbeld A., Koudstaal J., Gouw A. S., Sluiter W. J., Peeters P. M., Slooff M. J., De Vries E. G. Clinical relevance of transforming growth factor alpha, epidermal growth factor receptor, p53, and Ki67 in colorectal liver metastases and corresponding primary tumors. Hepatology. 1998 Oct;28(4):971–979. doi: 10.1002/hep.510280411. [DOI] [PubMed] [Google Scholar]
  9. Derynck R. Transforming growth factor alpha. Cell. 1988 Aug 26;54(5):593–595. doi: 10.1016/s0092-8674(88)80001-1. [DOI] [PubMed] [Google Scholar]
  10. Filipe M. I., Osborn M., Linehan J., Sanidas E., Brito M. J., Jankowski J. Expression of transforming growth factor alpha, epidermal growth factor receptor and epidermal growth factor in precursor lesions to gastric carcinoma. Br J Cancer. 1995 Jan;71(1):30–36. doi: 10.1038/bjc.1995.7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Hartwell L. Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells. Cell. 1992 Nov 13;71(4):543–546. doi: 10.1016/0092-8674(92)90586-2. [DOI] [PubMed] [Google Scholar]
  12. Husemann B. Cardia carcinoma considered as a distinct clinical entity. Br J Surg. 1989 Feb;76(2):136–139. doi: 10.1002/bjs.1800760210. [DOI] [PubMed] [Google Scholar]
  13. Iihara K., Shiozaki H., Tahara H., Kobayashi K., Inoue M., Tamura S., Miyata M., Oka H., Doki Y., Mori T. Prognostic significance of transforming growth factor-alpha in human esophageal carcinoma. Implication for the autocrine proliferation. Cancer. 1993 May 15;71(10):2902–2909. doi: 10.1002/1097-0142(19930515)71:10<2902::aid-cncr2820711004>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
  14. Imazeki F., Omata M., Nose H., Ohto M., Isono K. p53 gene mutations in gastric and esophageal cancers. Gastroenterology. 1992 Sep;103(3):892–896. doi: 10.1016/0016-5085(92)90022-q. [DOI] [PubMed] [Google Scholar]
  15. Jakl R. J., Miholic J., Koller R., Markis E., Wolner E. Prognostic factors in adenocarcinoma of the cardia. Am J Surg. 1995 Mar;169(3):316–319. doi: 10.1016/s0002-9610(99)80166-4. [DOI] [PubMed] [Google Scholar]
  16. Kajiyama Y., Tsurumaru M., Udagawa H., Tsutsumi K., Kinoshita Y., Ueno M., Akiyama H. Prognostic factors in adenocarcinoma of the gastric cardia: pathologic stage analysis and multivariate regression analysis. J Clin Oncol. 1997 May;15(5):2015–2021. doi: 10.1200/JCO.1997.15.5.2015. [DOI] [PubMed] [Google Scholar]
  17. MacFarlane S. D., Hill L. D., Jolly P. C., Kozarek R. A., Anderson R. P. Improved results of surgical treatment for esophageal and gastroesophageal junction carcinomas after preoperative combined chemotherapy and radiation. J Thorac Cardiovasc Surg. 1988 Mar;95(3):415–422. [PubMed] [Google Scholar]
  18. Malden L. T., Novak U., Burgess A. W. Expression of transforming growth factor alpha messenger RNA in the normal and neoplastic gastro-intestinal tract. Int J Cancer. 1989 Mar 15;43(3):380–384. doi: 10.1002/ijc.2910430305. [DOI] [PubMed] [Google Scholar]
  19. Martin H. M., Filipe M. I., Morris R. W., Lane D. P., Silvestre F. p53 expression and prognosis in gastric carcinoma. Int J Cancer. 1992 Apr 1;50(6):859–862. doi: 10.1002/ijc.2910500604. [DOI] [PubMed] [Google Scholar]
  20. Moskaluk C. A., Heitmiller R., Zahurak M., Schwab D., Sidransky D., Hamilton S. R. p53 and p21(WAF1/CIP1/SDI1) gene products in Barrett esophagus and adenocarcinoma of the esophagus and esophagogastric junction. Hum Pathol. 1996 Nov;27(11):1211–1220. doi: 10.1016/s0046-8177(96)90317-2. [DOI] [PubMed] [Google Scholar]
  21. Naito Y., Saito K., Shiiba K., Ohuchi A., Saigenji K., Nagura H., Ohtani H. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res. 1998 Aug 15;58(16):3491–3494. [PubMed] [Google Scholar]
  22. Nasim M. M., Thomas D. M., Alison M. R., Filipe M. I. Transforming growth factor alpha expression in normal gastric mucosa, intestinal metaplasia, dysplasia and gastric carcinoma--an immunohistochemical study. Histopathology. 1992 Apr;20(4):339–343. doi: 10.1111/j.1365-2559.1992.tb00991.x. [DOI] [PubMed] [Google Scholar]
  23. Ohno S., Tomisaki S., Oiwa H., Sakaguchi Y., Ichiyoshi Y., Maehara Y., Sugimachi K. Clinicopathologic characteristics and outcome of adenocarcinoma of the human gastric cardia in comparison with carcinoma of other regions of the stomach. J Am Coll Surg. 1995 May;180(5):577–582. [PubMed] [Google Scholar]
  24. Patel D. D., Bhatavdekar J. M., Chikhlikar P. R., Patel Y. V., Shah N. G., Ghosh N., Suthar T. P., Balar D. B. Clinical significance of p53, nm23, and bcl-2 in T3-4N1M0 oesophageal carcinoma: an immunohistochemical approach. J Surg Oncol. 1997 Jun;65(2):111–116. doi: 10.1002/(sici)1096-9098(199706)65:2<111::aid-jso7>3.0.co;2-a. [DOI] [PubMed] [Google Scholar]
  25. Paterson I. M., Easton D. F., Corbishley C. M., Gazet J. C. Changing distribution of adenocarcinoma of the stomach. Br J Surg. 1987 Jun;74(6):481–482. doi: 10.1002/bjs.1800740618. [DOI] [PubMed] [Google Scholar]
  26. Pera M., Cameron A. J., Trastek V. F., Carpenter H. A., Zinsmeister A. R. Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction. Gastroenterology. 1993 Feb;104(2):510–513. doi: 10.1016/0016-5085(93)90420-h. [DOI] [PubMed] [Google Scholar]
  27. Powell J., McConkey C. C. The rising trend in oesophageal adenocarcinoma and gastric cardia. Eur J Cancer Prev. 1992 Apr;1(3):265–269. doi: 10.1097/00008469-199204000-00008. [DOI] [PubMed] [Google Scholar]
  28. Ropponen K. M., Eskelinen M. J., Lipponen P. K., Alhava E., Kosma V. M. Prognostic value of tumour-infiltrating lymphocytes (TILs) in colorectal cancer. J Pathol. 1997 Jul;182(3):318–324. doi: 10.1002/(SICI)1096-9896(199707)182:3<318::AID-PATH862>3.0.CO;2-6. [DOI] [PubMed] [Google Scholar]
  29. Sauter E. R., Coia L. R., Eisenberg B. L., Hanks G. E. Transforming growth factor alpha expression as a potential survival prognosticator in patients with esophageal adenocarcinoma receiving high-dose radiation and chemotherapy. Int J Radiat Oncol Biol Phys. 1995 Feb 1;31(3):567–569. doi: 10.1016/0360-3016(94)00368-U. [DOI] [PubMed] [Google Scholar]
  30. Schreiber A. B., Winkler M. E., Derynck R. Transforming growth factor-alpha: a more potent angiogenic mediator than epidermal growth factor. Science. 1986 Jun 6;232(4755):1250–1253. doi: 10.1126/science.2422759. [DOI] [PubMed] [Google Scholar]
  31. Sharpe D. A., Moghissi K. Resectional surgery in carcinoma of the oesophagus and cardia: what influences long-term survival? Eur J Cardiothorac Surg. 1996;10(5):359–364. doi: 10.1016/s1010-7940(96)80095-9. [DOI] [PubMed] [Google Scholar]
  32. Sons H. U., Borchard F. Cancer of the distal esophagus and cardia. Incidence, tumorous infiltration, and metastatic spread. Ann Surg. 1986 Feb;203(2):188–195. doi: 10.1097/00000658-198602000-00013. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Stemmermann G., Heffelfinger S. C., Noffsinger A., Hui Y. Z., Miller M. A., Fenoglio-Preiser C. M. The molecular biology of esophageal and gastric cancer and their precursors: oncogenes, tumor suppressor genes, and growth factors. Hum Pathol. 1994 Oct;25(10):968–981. doi: 10.1016/0046-8177(94)90056-6. [DOI] [PubMed] [Google Scholar]
  34. Steup W. H., De Leyn P., Deneffe G., Van Raemdonck D., Coosemans W., Lerut T. Tumors of the esophagogastric junction. Long-term survival in relation to the pattern of lymph node metastasis and a critical analysis of the accuracy or inaccuracy of pTNM classification. J Thorac Cardiovasc Surg. 1996 Jan;111(1):85–95. doi: 10.1016/S0022-5223(96)70404-X. [DOI] [PubMed] [Google Scholar]
  35. Wang H. H., Antonioli D. A., Goldman H. Comparative features of esophageal and gastric adenocarcinomas: recent changes in type and frequency. Hum Pathol. 1986 May;17(5):482–487. doi: 10.1016/s0046-8177(86)80038-7. [DOI] [PubMed] [Google Scholar]
  36. Wang L. D., Shi S. T., Zhou Q., Goldstein S., Hong J. Y., Shao P., Qiu S. L., Yang C. S. Changes in p53 and cyclin D1 protein levels and cell proliferation in different stages of human esophageal and gastric-cardia carcinogenesis. Int J Cancer. 1994 Nov 15;59(4):514–519. doi: 10.1002/ijc.2910590414. [DOI] [PubMed] [Google Scholar]
  37. Wang L. S., Wu C. W., Hsieh M. J., Fahn H. J., Huang M. H., Chien K. Y. Lymph node metastasis in patients with adenocarcinoma of gastric cardia. Cancer. 1993 Mar 15;71(6):1948–1953. doi: 10.1002/1097-0142(19930315)71:6<1948::aid-cncr2820710604>3.0.co;2-s. [DOI] [PubMed] [Google Scholar]
  38. Webb J. N., Busuttil A. Adenocarcinoma of the oesophagus and of the oesophagogastric junction. Br J Surg. 1978 Jul;65(7):475–479. doi: 10.1002/bjs.1800650709. [DOI] [PubMed] [Google Scholar]
  39. Wu T. T., Watanabe T., Heitmiller R., Zahurak M., Forastiere A. A., Hamilton S. R. Genetic alterations in Barrett esophagus and adenocarcinomas of the esophagus and esophagogastric junction region. Am J Pathol. 1998 Jul;153(1):287–294. doi: 10.1016/S0002-9440(10)65570-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Yonemura Y., Takamura H., Ninomiya I., Fushida S., Tsugawa K., Kaji M., Nakai Y., Ohoyama S., Yamaguchi A., Miyazaki I. Interrelationship between transforming growth factor-alpha and epidermal growth factor receptor in advanced gastric cancer. Oncology. 1992;49(2):157–161. doi: 10.1159/000227031. [DOI] [PubMed] [Google Scholar]
  41. Younes M., Fernandez L., Lechago J. Transforming growth factor alpha (TGF-alpha) expression in biopsies of colorectal carcinoma is a significant prognostic indicator. Anticancer Res. 1996 Jul-Aug;16(4A):1999–2003. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES